Products - Renal cancer | Topic | NICE

Showing 3 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
15 May 2019
Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 April 2020
Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
27 May 2020